SCHEMBL6490476

SCHEMBL6490476

CC(=O)Nc1cccc(CN2CCN(c3ccc(NC(=O)C4=C(c5ccc(C)cc5)CCCC4)cc3)CC2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
HTT P42858 1/20 0.42
MAPT P10636 5/20 0.41
NPC1 O15118 3/20 0.41
KDM4E B2RXH2 3/20 0.41
RAB9A P51151 2/20 0.41
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MCL1 Q07820 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ALDH1A1 P00352 3/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
DGAT1 O75907 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6689632 0.93 MAPT (0.44) MEN1KMT2AHTTMAPTNPC1
SCHEMBL6492454 0.89 MAPT (0.41) MEN1KMT2AHTTMAPTNPC1
SCHEMBL6498772 0.82 MAPT (0.58) KMT2AHTTMAPTKDM4ERAB9A
SCHEMBL6499900 0.79 DRD2 (0.46) MEN1KMT2AMAPTNPC1KDM4E
SCHEMBL6502650 0.78 MAPT (0.47) MEN1KMT2AMAPTNPC1KDM4E
SCHEMBL6491504 0.78 FAAH (0.49) KMT2AHTTMAPTKDM4ERAB9A
SCHEMBL6499147 0.78 MAPT (0.46) MEN1KMT2AMAPTNPC1KDM4E
SCHEMBL6504210 0.77 KMT2A (0.45) MEN1KMT2AHTTMAPTNPC1
SCHEMBL6490132 0.75 LCK (0.39) MAPTNPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL6499989 0.75 NPC1 (0.53) MEN1KMT2AMAPTNPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 MEN1 1991/4885KMT2A 573/4885HTT 2574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.